PUBLIC CONTRACT · 2025
Aquisição de OLAPARIB ORAL 150MG COMP REV, AUE no 202302160, ao Lab. AstraZeneca, para a ULSASI, para o ano 2025
- Contract value
- €52,828.88
- Signed on
- 13 March 2025
- Procedure
- Contratação excluída II
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 15488794PUBLISHED SUBJECT
Aquisição de OLAPARIB ORAL 150MG COMP REV, AUE no 202302160, ao Lab. AstraZeneca, para a ULSASI, para o ano 2025
Parties involved
- Place of performance
- Portugal, Lisboa, Amadora
- NUTS region
- PT1A0 - Grande Lisboa
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- ASTRAZENECA-PRODUTOS FARMACÊUTICOS,LDA. · Tax ID 502942240
Values and timeline
- Contract price
- €52,828.88
- Procedure base price
- €52,828.88
- Total effective price
- Not reported on Portal BASE
- Publication date
- 13 August 2026
- Award date
- 13 March 2025
- Signing date
- 13 March 2025
- Performance period
- 293 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Contratação excluída II
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- artigo 5.º n.º 1 do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 11434820
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.